Improving therapy for NUT carcinoma using a genetically engineered mouse model
Genetically engineered mouse model to improve therapy of NUT carcinoma
This study is looking at a tough type of cancer called NUT carcinoma to find better ways to treat it, using specially designed mice to see how the cancer grows and how we might stop it with new medicines.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10931673 on NIH RePORTER |
What this research studies
This research focuses on NUT carcinoma, a highly aggressive cancer with limited treatment options and a very low survival rate. The team has developed a genetically engineered mouse model to better understand the mechanisms driving this cancer and to identify potential therapeutic targets. By studying how tumor cells interact with their environment, the researchers aim to discover new ways to inhibit cancer growth using specific small molecules known as BET bromodomain inhibitors. This approach could lead to more effective treatments for patients suffering from this lethal disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with NUT carcinoma, regardless of age.
Not a fit: Patients with other types of cancer or those not diagnosed with NUT carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and treatment options for patients with NUT carcinoma.
How similar studies have performed: Previous research has shown promise in using BET inhibitors for treating cancers driven by similar mechanisms, indicating potential for success in this novel approach.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: French, Christopher a — Brigham and Women's Hospital
- Study coordinator: French, Christopher a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.